The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11024 malaria professionals are enjoying the free benefits of MalariaWorld today

malaria vaccine

The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries

January 14, 2020 - 16:32 -- Open Access
Author(s): 
Sicuri E, Yaya Bocoum F, Nonvignon J, Alonso S, Fakih B, Bonsu G, Kariuki S, Leeuwenkamp O, Munguambe K, Mrisho M, Were V, Sauboin C
Reference: 
MDM Policy & Practice, 2019 Dec 19;4(2):2381468319896280

The World Health Organization has recommended pilot implementation of a candidate vaccine against malaria (RTS,S/AS01) in selected sub-Saharan African countries. This exploratory study aimed to estimate the costs of implementing RTS,S in Burkina Faso, Ghana, Kenya, Mozambique, and Tanzania.

Comparison of immunogenicity and safety outcomes of a malaria vaccine FMP013/ALFQ in rhesus macaques (Macaca mulatta) of Indian and Chinese origin

December 3, 2019 - 15:22 -- Open Access
Author(s): 
Monica L. Martin, Alexis A. Bitzer, Andrew Schrader, Elke S. Bergmann-Leitner, Kim Soto, Xiaoyan Zou, Zoltan Beck, Gary R. Matyas and Sheetij Dutta
Reference: 
Malaria Journal 2019 18:377, 27 November 2019

Indian-origin rhesus (InR) are preferred for research, but strict export restrictions continue to limit their use. Chinese-origin rhesus (ChR), although easier to procure, are genetically distinct from InR and differ in their immune response to infectious agents, such as the Simian Immunodeficiency Virus. The most advanced malaria vaccine, RTS,S (GlaxoSmithKline), is based on the circumsporozoite protein (CSP) of Plasmodium falciparum.

The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants

March 10, 2015 - 13:31 -- Open Access
Author(s): 
Anthony Ajua, Bertrand Lell, Benjamin Mordmüller, et al.
Reference: 
Malaria Journal 2015, 14:72 (13 February 2015)

So far, only the quantity of anti-CSP IgG has been measured and used to predict vaccination success, although quality (measured as avidity) of the antigen-antibody interaction shall be important since only a few sporozoites circulate for a short time after an infectious mosquito bite, likely requiring fast and strong binding.

Person: 
Country: 

Development of a transmission-blocking malaria vaccine: Progress, challenges, and the path forward

September 23, 2014 - 16:58 -- Open Access
Author(s): 
Julia K. Nunes, Colleen Woods, Terrell Carter, Theresa Raphael, Merribeth J. Morin, Diadier Diallo, Didier Leboulleux, Sanjay Jain, Christian Loucq, David C. Kaslow, Ashley J. Birkett
Reference: 
Vaccine, Volume 32, Issue 43, 29 September 2014, Pages 5531-5539

This article describes the progress made in critical areas since 2010, highlights key challenges that remain, and outlines important next steps to maximize the potential for SSM-VIMTs to contribute to the broader malaria elimination and eradication objectives.

The malaria vaccine – Status quo 2013

April 15, 2013 - 18:00 -- Open Access
Author(s): 
D. Gray Heppner
Reference: 
Travel Medicine and Infectious Disease, Volume 11, Issue 1, January–February 2013, Pages 2-7
MalariaWorld

Interim reports from this largest ever Phase III pediatric trial in Africa show the malaria vaccine decreased clinical and severe disease by 56% and 47% respectively in 5–17 month olds, and by 31% and 26% respectively in infants participating in the Expanded Programme on Immunization.

Pages

Subscribe to RSS - malaria vaccine